Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 4/2010

Open Access 01-12-2010

Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis

Author: Beata Lecka-Czernik

Published in: Current Osteoporosis Reports | Issue 4/2010

Login to get access

Abstract

Clinical evidence indicates that bone status is affected in patients with type 2 diabetes mellitus (T2DM). Regardless of normal or even high bone mineral density, T2DM patients have increased risk of fractures. One class of antidiabetic drugs, thiazolidinediones (TZDs), causes bone loss and further increases facture risk, placing TZDs in the category of drugs causing secondary osteoporosis. Risk factors for development of TZD-induced secondary osteoporosis are gender (women), age (elderly), and duration of treatment. TZDs exert their antidiabetic effects by activating peroxisome proliferator-activated receptor-γ (PPAR-γ) nuclear receptor, which controls glucose and fatty acid metabolism. In bone, PPAR-γ controls differentiation of cells of mesenchymal and hematopoietic lineages. PPAR-γ activation with TZDs leads to unbalanced bone remodeling: bone resorption increases and bone formation decreases. Laboratory research evidence points toward a possible separation of unwanted effects of PPAR-γ on bone from its beneficial antidiabetic effects by using selective PPAR-γ modulators. This review also discusses potential pharmacologic means to protect bone from detrimental effects of clinically used TZDs (pioglitazone and rosiglitazone) by using combinational therapy with approved antiosteoporotic drugs, or by using lower doses of TZDs in combination with other antidiabetic therapy. We also suggest a possible orthopedic complication, not yet supported by clinical studies, of delayed fracture healing in T2DM patients on TZD therapy.
Literature
1.
Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005, 172:213–226.PubMed
2.
Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289–312.CrossRefPubMed
3.
Lecka-Czernik B: PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010, 8:84–90.CrossRefPubMed
4.
• Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009, 10:1085–1090. This article reviews the effect of T2DM and different antidiabetic therapies on the human skeleton.PubMed
5.
Janghorbani M, Van Dam RM, Willett WC, Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007, 166:495–505.CrossRefPubMed
6.
Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009, 24:702–709.CrossRefPubMed
7.
Vestergaard P, Rejnmark L, Mosekilde L: Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009, 84:45–55.CrossRefPubMed
8.
Schwartz AV, Hillier TA, Sellmeyer DE, et al.: Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002, 25:1749–1754.CrossRefPubMed
9.
Melton LJ, Leibson CL, Achenbach SJ, et al.: Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334–1342.CrossRefPubMed
10.
Krakauer JC, McKenna MJ, Buderer NF, et al.: Bone loss and bone turnover in diabetes. Diabetes 1995, 44:775–782.CrossRefPubMed
11.
Huang S, Kaw M, Harris MT, et al.: Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 2010, 46:1138–1145.CrossRefPubMed
12.
Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013–1019.CrossRefPubMed
13.
Vashishth D: Collagen glycation and its role in fracture properties of bone. J Musculoskelet Neuronal Interact 2005, 5:316.PubMed
14.
• Schwartz AV, Garnero P, Hillier TA, et al.: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:2380–2386. This study shows association between levels of circulating AGEs and increased fracture risk in T2DM patients.CrossRefPubMed
15.
Deeg MA, Tan MH: Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.PubMed
16.
Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.CrossRefPubMed
17.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.CrossRefPubMed
18.
Wadman M: Avandia outcome may signal change in epidemiologists’ sway. Nat Med 2010, 16:614.
19.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.CrossRefPubMed
20.
21.
Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349–3354.CrossRefPubMed
22.
Kanazawa I, Yamaguchi T, Yano S, et al.: Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 2010 Feb 4 [Epub ahead of print].
23.
Glintborg D, Andersen M, Hagen C, et al.: Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008, 93:1696–1701.CrossRefPubMed
24.
Grey A, Bolland M, Gamble G, et al.: The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305–1310.CrossRefPubMed
25.
Gruntmanis U, Fordan S, Ghayee HK, et al.: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010, 86:343–349.CrossRefPubMed
26.
• Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845–851. This article provides a retrospective analysis of fracture risk and type of fractures among the ADOPT participants receiving rosiglitazone.CrossRefPubMed
27.
Zinman B, Haffner SM, Herman WH, et al.: Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:134–142.CrossRefPubMed
28.
• Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32–39. This article provides a comprehensive review of available clinical trials in respect to the effect of TZDs on risk of fractures.PubMed
29.
Jones SG, Momin SR, Good MW, et al.: Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009, 15:491–496.PubMed
30.
Habib ZA, Havstad SL, Wells K, et al.: Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592–600.CrossRefPubMed
31.
Dormuth CR, Carney G, Carleton B, et al.: Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395–1402.CrossRefPubMed
32.
Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820–825.CrossRefPubMed
33.
Solomon DH, Cadarette SM, Choudhry NK, et al.: A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009, 94:2792–2798.CrossRefPubMed
34.
Douglas IJ, Evans SJ, Pocock S, Smeeth L: The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009, 6:e1000154.CrossRefPubMed
35.
Gradiser M, Matovinovic M, Vrkljan M: Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J 2007, 48:87–91.PubMed
36.
Gatti D, Viapiana O, Rossini M, Silvano A: Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressive. J Bone Miner Res 2010, 25:1460–1462.PubMed
37.
Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401–406.CrossRefPubMed
38.
Lazarenko OP, Rzonca SO, Hogue WR, et al.: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669–2680.CrossRefPubMed
39.
Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75:329–337.CrossRefPubMed
40.
41.
Modder UI, Monroe DG, Fraser DG, et al.: Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem 2009, 284:18767–18777.CrossRefPubMed
42.
Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13:1496–1503.CrossRefPubMed
43.
Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638–649.CrossRefPubMed
44.
• Shockley KR, Lazarenko OP, Czernik PJ, et al.: PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232–246. This article provides an extensive analysis of the effect of rosiglitazone on gene expression in marrow MSCs.CrossRefPubMed
45.
• Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B: PPARgamma2 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Res 2007, 2007:81219. This article demonstrates that PPAR-γ2 plays a major role in regulation of cell "stemness." PubMed
46.
Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379–389.CrossRefPubMed
47.
Rosen CJ, Bouxsein ML: Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35–43.CrossRefPubMed
48.
Cao JJ, Wronski TJ, Iwaniec U, et al.: Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 2005, 20:1659–1668.CrossRefPubMed
49.
Higgins LS, Depaoli AM: Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010, 91:267 S–272 S.CrossRefPubMed
50.
Glass CK, Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365–376.CrossRefPubMed
51.
Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376–2384.CrossRefPubMed
52.
Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B: Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006, 38:74–85.CrossRefPubMed
53.
Stafford JM, Elasy T: Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 2007, 3:503–510.PubMed
54.
Wong IP, Baldock PA, Herzog H: Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes 2010, 17:44–50.PubMed
55.
Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224–1230.CrossRefPubMed
Metadata
Title
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Author
Beata Lecka-Czernik
Publication date
01-12-2010
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 4/2010
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-010-0027-y

Other articles of this Issue 4/2010

Current Osteoporosis Reports 4/2010 Go to the issue

ReviewPaper

The Skeletal Subsystem as an Integrative Physiology Paradigm

ReviewPaper

The Definition and Clinical Significance of Nonvertebral Fractures

INVITED COMMENTARY

Denosumab for the Treatment of Osteoporosis

ReviewPaper

HIV and Bone Loss

ReviewPaper

Depression, Selective Serotonin Reuptake Inhibitors, and Osteoporosis

ReviewPaper

The Role of FSH and TSH in Bone Loss and Its Clinical Relevance